The Food and Drug Administration on Sept. 15 released the final design of its Expedited Investigational New Drug (IND) Pilot and began accepting applications from drugmakers and research partners. Drug sponsors and qualified research institutions must apply as pairs by Oct. 30, 2026, and the agency expects to select eight to 10 pairs for its first group.
Update Note: This article reports new information on the FDA's Expedited IND Pilot following MedicalDaily's earlier coverage of the proposal's public comment period. The latest verified information comes from the FDA's announcement dated Sept. 15, 2026.
An IND is the application a drug sponsor must have in effect before giving an experimental medicine to people in the United States. After it is submitted, the FDA generally has 30 days to review it and can place the study on hold. The pilot aims to shorten the time before that first human dose. It does not change what it takes for a drug to win approval, and the standards for safety and effectiveness stay the same.
For families living with serious illnesses, the distinction is important. A faster start to early testing may eventually widen access to experimental options in U.S. hospitals, but it will not, by itself, put new drugs on pharmacy shelves any sooner.
Final Pilot Design Reaches Beyond the FDA Review
The FDA says first-in-human trials can take up to two years in the United States, while similar studies move much faster in China and Australia. The pilot is part of Operation TrialBlazer, a Department of Health and Human Services initiative announced in June.
Under the final design, selected research institutions will bring scientific expertise to the preparation of IND applications. That will let the FDA review individual parts of an application on a rolling basis before the full application arrives. The agency says this may help catch problems earlier and reduce the risk of a clinical hold during the 30-day review.
The final design also goes beyond the review itself. The FDA says the pilot will test whether the partnership can speed up what happens after the agency allows a trial to proceed. It encourages ethics board review and trial site activation to happen alongside IND development where appropriate.
According to BioPharma Dive, Karim Mikhail, director of the FDA's Center for Biologics Evaluation and Research, said rolling reviews can help the agency "identify and resolve issues earlier, reduce the risk of clinical hold, and make the path to first-in-human trials faster and more predictable." An FDA spokesperson told the outlet that academic research centers and contract research organizations could qualify as partners and that smaller companies and startups may apply.
The FDA says it keeps full authority over whether any trial may proceed and whether to impose a clinical hold. Its pilot webpage lists eligibility rules, conflict-of-interest requirements, and selection criteria.
Earlier Critiques and Questions Still Open
MedicalDaily reported on Aug. 24, as the public comment window on the proposal closed, that the plan was still only a request for information. That coverage highlighted arguments that many early-trial delays happen at hospitals and ethics boards rather than at the FDA.
The final design responds to part of that concern by encouraging site activation and ethics review to run in parallel. It does not require those steps, however, and the announcement does not explain how the FDA will measure whether they happen faster.
Michael Davis, director of the FDA's Center for Drug Evaluation and Research, said in the announcement that the agency had "incorporated that feedback into the final pilot design."
Industry support is not unconditional. BioPharma Dive reported that the Biotechnology Innovation Organization said in August that rolling review would likely save significant time. The trade group also questioned whether any single institution could meet the FDA's requirements and warned that the arrangement could add another layer of review.
Several questions remain unanswered. The FDA has not said when it will name the selected pairs, and no data yet show that the approach shortens timelines. The first group will also be small. The FDA says the pilot may inform a future formal accreditation model for research institutions, but that outcome is not guaranteed.
Oversight of conflicts also deserves attention. Because institutions will help sponsors prepare applications, the strength of the FDA's conflict-of-interest rules will matter as the pilot moves forward.
Patients Seeking Early Trials Should Keep Expectations Measured
The people most affected are patients with rare diseases or advanced cancers who look to early-phase studies after standard treatments stop working. First-in-human trials mainly determine proper dosing and how the body absorbs and handles a drug. Many experimental drugs that enter early testing never reach approval, and participants accept risks without a guarantee of personal benefit.
Patients interested in trials do not need to wait for this pilot. Current studies can be searched on ClinicalTrials.gov, and oncologists or other specialists can help judge whether a study fits a person's situation. Before enrolling, patients can ask the study coordinator about travel costs, lodging, time away from work, and what their insurance will cover. The pilot does not address those expenses.
No one should stop an established treatment to pursue an experimental one without first talking with a qualified clinician. Anyone in a trial who develops severe or rapidly worsening symptoms should contact the study team right away or seek emergency care.
The application window closes Oct. 30, after which FDA scientific experts will review the submissions. MedicalDaily will report when the agency names its first participants and releases any data on timelines.
The pilot could make the early stages of drug testing faster and more predictable in the United States. For now, it is a small experiment that leaves approval standards unchanged and offers no immediate change for patients.
Key Questions Answered
What did the FDA announce? The FDA finalized its Expedited IND Pilot on Sept. 15 and is accepting applications through Oct. 30, 2026. It expects to select eight to 10 sponsor and research institution pairs.
What is an IND? An investigational new drug application must be in effect before an experimental drug is given to people in the United States. The FDA generally has 30 days to review it and can place a study on hold.
Will this make drug approvals faster? No. The pilot targets the time before first-in-human trials begin. Approval standards are unchanged.
What changed from the original proposal? The final design encourages ethics board review and trial site activation to happen alongside application development, and it tests whether the partnership speeds up steps after the FDA allows a trial to proceed.
Who can apply? Drug sponsors apply together with a qualified research institution. An FDA spokesperson said academic centers and contract research organizations could qualify, and smaller companies may apply.
Does the FDA give up any safety authority? No. The agency says it keeps full authority over whether a trial may proceed and whether to impose a clinical hold.
How can patients find a clinical trial now? Patients can search ClinicalTrials.gov and ask their doctor or a study coordinator about eligibility, costs, and travel.
